Antiretroviral Drugs Market: By Drug Class, Non- Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Others), By Administration, By Distribution Channel, and Region Forecast 2019-2030

Antiretroviral Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Nucleoside Reverse Transcriptase Inhibitors (NRT), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Others), By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Region Forecast 2019-2030

Antiretroviral Drugs Market size was valued at US$ 63.9 billion in 2023 and is poised to grow at a CAGR of 4.9% from 2024-2030. Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-cell leukemia. Acquired immune deficiency syndrome (AIDS) is caused by the retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that act or inhibit certain processes in viral replication and inhibit further worsening of the diseases. Globally antiviral drugs market is driven by increased cases of retroviral infections such as especially HIV/AIDS.

According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS-related illness in the same year. The higher prevalence of HIV owing to various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, and increased funding by the government are expected to bolster the market over the forecast period. However, high costs of R&D and stringent regulatory procedures hamper the Market.

Furthermore, the availability of generic versions of blockbuster drugs affects the market revenue of antiretroviral drugs. The market is expected to grow at significant rates during the forecasting period owing to pipeline drugs such as etravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec), etc. Market players are adopting strategies like mergers and acquisitions to improve their market share.

Antiretroviral Drugs Market Key Developments

  • In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb's late-stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases.
  • In September 2016, to eradicate and combat HIV/AIDS and hypertension in Africa, under the U.S. President Emergency Plan for Aids Relief (PEPFAR), the United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding.
  • In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline's joint venture) received U.S. FDA approval to market see entry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.  

Global Antiretroviral Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.9%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Antiretroviral Drugs Market Dynamics

However, as viral illnesses such as HIV, Herpes, Influenza, and others become more common, demand for antiviral drugs is likely to rise over the forecast period. According to UNAIDS, more than 37 million people around the world would be living with HIV by 2020. In 2020, around 1.5 million more people will have contracted HIV. Overall, the COVID-19 pandemic has greatly improved market growth in 2020, however the pandemic has had a negative influence on other antiviral drug applications. Over the predicted period, a primary element driving demand for antiviral medications is the rising incidence of viral illness over the world.

According to the WHO, an estimated 325 million individuals worldwide have hepatitis, with 71 million of these having chronic hepatitis C virus infection. Furthermore, the United States Department of Health and Human Services estimates that 2.4 million people in the country have hepatitis C, with roughly 850,000 people infected with hepatitis B. The global need for antiviral medications is expected to rise as the number of patients grows.

Global Antiretroviral Drugs Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 63.9 billion

Market CAGR

4.9%

By Drug Class

  • Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
  • Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
  • Protease Inhibitors
  • Integrate Inhibitors
  • Fusion Inhibitors
  • Chemokine Receptor Inhibitors
  • Others

By Administration

  • Oral
  • Parenteral

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Key Features of the Report

  • The antiretroviral drugs market report  provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

The global antiretroviral drugs market size was valued at US$ 63.9 billion in 2023 and is projected to grow at a CAGR of 4.9% from 2024 to 2030.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The antiretroviral drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

 

1. Executive Summary
2. Global Antiretroviral Drugs Market Introduction 
2.1.Global Antiretroviral Drugs Market  - Taxonomy
2.2.Global Antiretroviral Drugs Market  - Definitions
2.2.1.Drug Class
2.2.2.Administration
2.2.3. Distribution channel
2.2.4.Region
3. Global Antiretroviral Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID-19 on Market
4. Global Antiretroviral Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Antiretroviral Drugs Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Protease Inhibitors
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Integrate Inhibitors
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Fusion Inhibitors
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Chemokine Receptor Inhibitors
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Others
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
6. Global Antiretroviral Drugs Market  By Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Parenteral
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Global Antiretroviral Drugs Market  By  Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8. Global Antiretroviral Drugs Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Antiretroviral Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
9.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
9.1.3.Protease Inhibitors
9.1.4.Integrate Inhibitors
9.1.5.Fusion Inhibitors
9.1.6.Chemokine Receptor Inhibitors
9.1.7.Others
9.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Parenteral
9.3.   Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.3.4.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Antiretroviral Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
10.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
10.1.3.Protease Inhibitors
10.1.4.Integrate Inhibitors
10.1.5.Fusion Inhibitors
10.1.6.Chemokine Receptor Inhibitors
10.1.7.Others
10.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Parenteral
10.3.   Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.3.4.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Antiretroviral Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
11.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
11.1.3.Protease Inhibitors
11.1.4.Integrate Inhibitors
11.1.5.Fusion Inhibitors
11.1.6.Chemokine Receptor Inhibitors
11.1.7.Others
11.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Parenteral
11.3.   Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.3.4.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Antiretroviral Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
12.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
12.1.3.Protease Inhibitors
12.1.4.Integrate Inhibitors
12.1.5.Fusion Inhibitors
12.1.6.Chemokine Receptor Inhibitors
12.1.7.Others
12.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Parenteral
12.3.   Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.3.4.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Antiretroviral Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
13.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
13.1.3.Protease Inhibitors
13.1.4.Integrate Inhibitors
13.1.5.Fusion Inhibitors
13.1.6.Chemokine Receptor Inhibitors
13.1.7.Others
13.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Parenteral
13.3.   Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.3.4.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.F. Hoffmann-La Roche Ltd.
14.2.2.GlaxoSmithKline plc
14.2.3.AbbVie
14.2.4.Merck & Co., Inc.
14.2.5.Johnson & Johnson Services, Inc.
14.2.6.Bristol-Myers Squibb Company
14.2.7.Cipla Inc.
14.2.8.Aurobindo Pharma
14.2.9.Dr. Reddy?s Laboratories Ltd.
15. Research Methodology 

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy?s Laboratories Ltd.

Related Industry Reports